I was a little negative re the vaccine business and will need convincing for its full retention. I believe that the average annual spend is $2.5m. If we get the $1.5m research grant based on the vaccine work then that might convince the market to retain the vaccine division as the potential is only costing $1m net per annum unless the adapt work qualifies partially for the grant.Clarification would be welcome. I would prefer to partner the vaccine business as the time frame is lengthy and will be a distraction for the adapt progress which I expect in the next quarter or two.
any reason for share price wilting?, page-18
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.68 |
Change
0.680(4.53%) |
Mkt cap ! $331.4M | |||
| Open | High | Low | Value | Volume |
| $14.90 | $15.75 | $14.85 | $431.9K | 28.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200 | $15.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.95 | 300 | 1 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |